JP2019524727A5 - - Google Patents

Download PDF

Info

Publication number
JP2019524727A5
JP2019524727A5 JP2019501566A JP2019501566A JP2019524727A5 JP 2019524727 A5 JP2019524727 A5 JP 2019524727A5 JP 2019501566 A JP2019501566 A JP 2019501566A JP 2019501566 A JP2019501566 A JP 2019501566A JP 2019524727 A5 JP2019524727 A5 JP 2019524727A5
Authority
JP
Japan
Prior art keywords
weight
pulsatile release
pharmaceutical composition
release pharmaceutical
levodopa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019501566A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019524727A (ja
JP7227896B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/067348 external-priority patent/WO2018011181A1/en
Publication of JP2019524727A publication Critical patent/JP2019524727A/ja
Publication of JP2019524727A5 publication Critical patent/JP2019524727A5/ja
Priority to JP2022092712A priority Critical patent/JP7534354B2/ja
Application granted granted Critical
Publication of JP7227896B2 publication Critical patent/JP7227896B2/ja
Priority to JP2024125641A priority patent/JP2024156827A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019501566A 2016-07-11 2017-07-11 朝の無動状態を治療するための拍動性薬物送達系 Active JP7227896B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022092712A JP7534354B2 (ja) 2016-07-11 2022-06-08 朝の無動状態を治療するための拍動性薬物送達系
JP2024125641A JP2024156827A (ja) 2016-07-11 2024-08-01 朝の無動状態を治療するための拍動性薬物送達系

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201670516 2016-07-11
DKPA201670516 2016-07-11
PCT/EP2017/067348 WO2018011181A1 (en) 2016-07-11 2017-07-11 Pulsatile drug delivery system for treating morning akinesia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022092712A Division JP7534354B2 (ja) 2016-07-11 2022-06-08 朝の無動状態を治療するための拍動性薬物送達系

Publications (3)

Publication Number Publication Date
JP2019524727A JP2019524727A (ja) 2019-09-05
JP2019524727A5 true JP2019524727A5 (https=) 2020-07-30
JP7227896B2 JP7227896B2 (ja) 2023-02-22

Family

ID=59383543

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019501566A Active JP7227896B2 (ja) 2016-07-11 2017-07-11 朝の無動状態を治療するための拍動性薬物送達系
JP2022092712A Active JP7534354B2 (ja) 2016-07-11 2022-06-08 朝の無動状態を治療するための拍動性薬物送達系
JP2024125641A Pending JP2024156827A (ja) 2016-07-11 2024-08-01 朝の無動状態を治療するための拍動性薬物送達系

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022092712A Active JP7534354B2 (ja) 2016-07-11 2022-06-08 朝の無動状態を治療するための拍動性薬物送達系
JP2024125641A Pending JP2024156827A (ja) 2016-07-11 2024-08-01 朝の無動状態を治療するための拍動性薬物送達系

Country Status (9)

Country Link
US (3) US11975104B2 (https=)
EP (2) EP3481385B1 (https=)
JP (3) JP7227896B2 (https=)
KR (1) KR102443161B1 (https=)
CN (1) CN109689036A (https=)
AU (3) AU2017297718B2 (https=)
CA (1) CA3030089C (https=)
ES (1) ES3041483T3 (https=)
WO (1) WO2018011181A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017297718B2 (en) * 2016-07-11 2023-06-08 Contera Pharma A/S Pulsatile drug delivery system for treating morning akinesia
JP7066351B2 (ja) * 2017-08-18 2022-05-13 大原薬品工業株式会社 良好な徐放性を有する、レボドパ含有小型化錠剤
US11389398B2 (en) 2019-05-14 2022-07-19 Clexio Biosciences Ltd. Gastroretentive treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
CA3142240A1 (en) * 2019-06-03 2020-12-10 Synthetic Biologics, Inc. Alkaline phosphatase formulations and uses thereof
EP3854385A1 (en) 2020-01-27 2021-07-28 ROS Therapeutics ApS Methotrexate dosage form
CN111084777A (zh) * 2020-02-11 2020-05-01 山西卫生健康职业学院 一种吡贝地尔、左旋多巴与苄丝肼复方缓释三层片剂及其制备方法
KR20230124622A (ko) * 2020-12-22 2023-08-25 암닐 파마슈티컬스 엘엘씨 레보도파 투여 요법
KR102903389B1 (ko) * 2022-11-30 2025-12-23 주식회사한국파마 신경퇴행성 질환 예방 또는 치료용 필름코팅정제
WO2024120389A1 (zh) * 2022-12-05 2024-06-13 上海汉都医药科技有限公司 延迟定时释放的药物组合物及其制备方法和应用
WO2025172348A1 (en) * 2024-02-12 2025-08-21 Contera Pharma A/S Delayed dual-pulse oral formulation
WO2025240494A1 (en) 2024-05-13 2025-11-20 Lumen Bioscience, Inc. Leptin compositions and methods of making and using the same to support weight loss and/or maintenance

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3253023A (en) 1963-09-27 1966-05-24 Dow Chemical Co Recovery of 3-(3, 4-dihydroxyphenyl)-l-alanine from velvet beans
BE759371A (fr) 1969-11-24 1971-05-24 Bristol Myers Co Azaspirodecanediones heterocycliques et procedes pour leur preparation
US3976776A (en) 1972-12-06 1976-08-24 Mead Johnson & Company Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4182763A (en) 1978-05-22 1980-01-08 Mead Johnson & Company Buspirone anti-anxiety method
US4356108A (en) 1979-12-20 1982-10-26 The Mead Corporation Encapsulation process
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4438119A (en) 1982-12-23 1984-03-20 Mead Johnson & Company Method for alleviation of extrapyramidal motor disorders
US4640921A (en) 1986-02-04 1987-02-03 Bristol-Myers Treatment of sexual dysfunction with buspirone
US4832957A (en) 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4687772A (en) 1986-10-07 1987-08-18 Bristol-Myers Company Method for improvement of short term memory
US4777173A (en) 1987-03-25 1988-10-11 Bristol-Myers Company Method for treatment of alcohol abuse
US5185329A (en) 1988-08-30 1993-02-09 Bristol-Myers Squibb Company Method for treatment of substance addiction
US6432956B1 (en) 1990-02-12 2002-08-13 William C. Dement Method for treatment of sleep apneas
PT97888B (pt) 1990-06-07 1998-12-31 Zeneca Ltd Processo para a preparacao de compostos heterociclicos derivados de indol e de composicoes farmaceuticas que os contem
US5633009A (en) 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
US5431922A (en) 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
DE4122217C2 (de) 1991-07-04 1997-02-13 Merz & Co Gmbh & Co Verfahren zur Herstellung mechanisch stabiler, gut zerfallender Komprimate aus kleinen wirkstoffhaltigen Formkörpern
GB9209882D0 (en) 1992-05-07 1992-06-24 Glaxo Lab Sa Compositions
US5484788A (en) 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
US5637314A (en) 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
GB9816556D0 (en) 1998-07-30 1998-09-30 Pfizer Ltd Therapy
US20080118556A1 (en) * 1998-11-02 2008-05-22 Elan Corporation, Plc Modified Release of Compositions Containing a Combination of Carbidopa, Levodopa and Entacapone
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US6150365A (en) 1999-08-05 2000-11-21 Bristol-Myers Squibb Company Anxiety method
GB9928578D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
ATE374192T1 (de) 2000-11-29 2007-10-15 Lilly Co Eli 1-(2-m-methansulfonamidophenylethyl)-4-(m- trifluoromethylphenyl)piperazine und ihre akzeptablen pharmazeutischen salze und solvate und ihre verwendung zur behandlung von inkontinenz
AU2002241565A1 (en) 2001-01-05 2002-07-16 Eli Lilly And Company Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
US8329734B2 (en) 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
RU2325152C2 (ru) 2001-07-04 2008-05-27 Сан Фармасьютикл Индастриз Лимитид Удерживаемая в желудке система регулируемой доставки лекарственного средства
PL208787B1 (pl) 2001-09-19 2011-06-30 Merck Patent Gmbh (2R, 4R/S)-2-({[5-(4-fluorofenylo)-pirydyn-3ylmetylo)]-amino}-metylo)-chroman-4-ol i (2R, 4R)-2-({[5-(4-fluorofenylo)-pirydyn-3ylmetylo)]-amino}-metylo)-chroman-4-ol, sposoby ich otrzymywania i zastosowanie do wytwarzania preparatów medycznych oraz zawierająca je kompozycja farmaceutyczna
US7094427B2 (en) 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20030224045A1 (en) 2002-05-29 2003-12-04 Chien-Hsuan Han Combination immediate release sustained release levodopa/carbidopa dosage forms
KR20050016449A (ko) * 2002-05-29 2005-02-21 임팩스 라보라토리즈, 인코포레이티드 레보도파/카르비도파의 즉시 방출 및 제어 방출 조합 투여형
MXPA06003813A (es) 2003-10-10 2006-06-14 Lifecycle Pharma As Forma solida de dosificacion que comprende un fibrato y una estatina.
DE10353657A1 (de) 2003-11-17 2005-06-23 Merck Patent Gmbh Indolderivate
US7470435B2 (en) 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
US20070173536A1 (en) 2004-02-06 2007-07-26 Ciba Specialty Chemicals Holding Inc. Crystalline forms of zolmitriptan
US20070155755A1 (en) 2004-02-23 2007-07-05 Wei Edward T N-arylshydroxyalkylidene-carboxamide compositions and methods
CA2572292A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
EP1791599A1 (en) 2004-09-07 2007-06-06 Pfizer Limited Combination of a 5-ht(1) receptor agonist and an alpha-2-delta ligand for the treatment of migraine
EP2623099A1 (en) * 2004-11-24 2013-08-07 Neuromolecular Pharmaceuticals, Inc Composition and method for treating neurological disease
JP2008526984A (ja) 2005-01-18 2008-07-24 メルク エンド カムパニー インコーポレーテッド Cgrp受容体拮抗薬
US20080166407A1 (en) 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
US9066903B2 (en) 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
WO2007129329A2 (en) 2006-05-08 2007-11-15 Jubilant Organosys Limited Extended release pharmaceutical formulation comprising venlafaxine hydrochloride
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス,インコーポレイティド 5ht受容体介在性の神経新生
KR20090033871A (ko) 2006-06-16 2009-04-06 솔베이 파마슈티칼스 비. 브이 비페프루녹스 및 l-dopa를 포함하는 병용 제제
US20080069874A1 (en) 2006-09-15 2008-03-20 Auriga Laboratories, Inc. Kits for Prevention and Treatment of Rhinitis
WO2008047839A1 (en) 2006-10-19 2008-04-24 Dainippon Sumitomo Pharma Co., Ltd. 5-ht1a receptor agonist
AU2007338631A1 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
EP1970056A1 (en) * 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
US20080226715A1 (en) 2007-03-16 2008-09-18 Albert Cha Therapeutic compositions and methods
EP2170282A4 (en) 2007-06-27 2014-11-05 Hanmi Pharm Ind Co Ltd METHOD FOR PRODUCING A QUICKLY CRUSHING FORMULATION FOR ORAL ADMINISTRATION AND DEVICE FOR PREPARING AND PACKAGING THE FORMULATION
CN101910113A (zh) 2007-12-28 2010-12-08 怡百克制药公司 左旋多巴控释制剂及其用途
EP2252284B1 (en) 2008-02-06 2011-05-25 Wockhardt Research Centre Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability
EP2105130A1 (de) 2008-03-25 2009-09-30 Ratiopharm GmbH Pharmazeutische Formulierung und Verfahren zu deren Herstellung
CN102149369B (zh) 2008-04-18 2016-08-10 因泰克制药有限公司 卡比多巴/左旋多巴胃滞留给药
EP2317996A1 (en) 2008-06-24 2011-05-11 Anders Björklund Eltoprazine for suppression of l-dopa induced dyskinesias
ES2592882T3 (es) 2008-10-14 2016-12-02 Mcneil Ab Forma de dosificación intra-oral de múltiples porciones y uso de la misma
SG196810A1 (en) 2009-01-23 2014-02-13 Acraf Controlled release pharmaceutical or foodformulation and process for its preparation
IN2012DN04858A (https=) 2009-12-23 2015-09-25 Map Pharmaceuticals Inc
CN101987081B (zh) * 2010-07-16 2012-08-08 钟术光 一种控释制剂
SI2627328T1 (sl) 2010-10-15 2017-01-31 Contera Pharma Aps Kombinacije agonistov receptorjev serotonina za zdravljenje motenj premikanja
WO2012059815A1 (en) * 2010-11-01 2012-05-10 Intec Pharma Ltd. Accordion pill comprising levodopa for an improved treatment of parkinson's disease symptoms
US20140221385A1 (en) 2011-06-01 2014-08-07 Concit Pharma Aps Combinations of serotonin receptor agonists for treatment of movement disorders
US20130195973A1 (en) 2012-01-30 2013-08-01 Ranbaxy Laboratories Limited Extended release pharmaceutical dosage forms of carbidopa and levodopa and process of preparation thereof
CA2973701A1 (en) 2015-01-13 2016-07-21 Amarantus Bioscience Holdings, Inc. Methods of treating motor and movement disorders and side effects thereof associated with parkinson's disease treatments
AU2017297718B2 (en) * 2016-07-11 2023-06-08 Contera Pharma A/S Pulsatile drug delivery system for treating morning akinesia

Similar Documents

Publication Publication Date Title
JP2019524727A5 (https=)
US7094427B2 (en) Combination immediate release controlled release levodopa/carbidopa dosage forms
JP7534354B2 (ja) 朝の無動状態を治療するための拍動性薬物送達系
JP2020059755A (ja) 時限パルス放出システム
US20070166375A1 (en) Modified release oral dosage form using co-polymer of polyvinyl acetate
RU2009115439A (ru) Фармацевтические композиции, включающие модулятор s1р
JP6359022B2 (ja) ヒドロモルホンおよびナロキソンを含む医薬組成物
ES2408343B2 (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
AU2003247409B2 (en) Combination immediate release controlled release levodopa/carbidopa dosage forms
BR102016010170B1 (pt) Composição farmacêutica estável de liberação prolongada
RU2642962C9 (ru) Терапия болезни паркинсона с применением комбинации с фиксированными дозами
JP2017119692A (ja) 圧縮成型製剤
WO2021129735A1 (zh) 一种固体制剂及其制备方法和用途
ES2663357T3 (es) Formulaciones de mazindol
MX2015001188A (es) Formulacion farmaceutica para reducir la frecuencia de miccion y metodo de uso de la misma.
JP2015193635A (ja) 速溶性防湿フィルムコーティング製剤及びその製造方法
US20050220873A1 (en) Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
RU2018137323A (ru) Пероральные фармацевтические композиции никотинамида
CA2954474C (en) Capsule dosage form of metoprolol succinate
CN100546653C (zh) 包含血管紧张素ⅱ1型受体拮抗剂的择时释放制剂
JP4926495B2 (ja) イブプロフェン含有コーティング顆粒
WO2009024858A1 (en) Controlled release dosage form of galantamine
RU2019109050A (ru) Композиции тезофензина
US20050220874A1 (en) Pharmaceutical dosage forms having immediate release and controlled release properties that contain a GABAB receptor agonist
US20080299189A1 (en) Controlled release dopamine agonist compositions